OKYO’s eye drop OK-101 has hit endpoints for ocular pain, tear film breakup time and conjunctival staining in Phase II, while demonstrating a placebo-like tolerability profile.

The PharmaMar subsidiary is the latest group to crash in a notoriously hard-to-treat disease, leaving Bausch + Lomb more firmly in command of the field.

Daewoong Innovation Holdings President Thierry Uh tells Scrip what Korean pharma firms should keep in mind when entering the US market, as well as what R&D and partnering strategies Daewoong has both there and globally.

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.